News Article | May 17, 2017
BOSTON--(BUSINESS WIRE)--Dr. Howard Birnbaum and Paul Greenberg, both of Analysis Group, have co-edited a book entitled Decision Making in a World of Comparative Effectiveness Research that is intended to serve as a guide for real-world analysis. Published by Springer, the book is a practical guide to decision making using CER—that is, observational data in real-world settings. CER considers the effectiveness of comparative evidence from many data sources, including electronic medical records, administrative claims, patient surveys, and clinical trials. This type of evidence can yield new insights into the effectiveness of alternative medical treatments. Unlike other books about CER that have focused on methodologies, Decision Making in a World of Comparative Effectiveness Research includes in-depth analysis from prominent stakeholders across the medical field, including senior industry executives, key opinion leaders, accomplished researchers, and attorneys. Geared toward global CER decision makers within the life sciences industry and government, the book covers, among other topics, the future of CER for evidence developers; evolving stakeholder considerations; and emerging challenges, methods, and applications of CER. Decision Making in a World of Comparative Effectiveness Research is now available for purchase on the Springer and Amazon websites. Analysis Group is one of the largest private economics consulting firms, with more than 700 professionals across 11 offices in the United States, Canada, and China. Since 1981, we have provided expertise in economics, finance, health care analytics, and strategy to top law firms, Fortune 500 companies, and government agencies worldwide. Our internal experts, together with our network of affiliated experts from academia, industry, and government, offer our clients exceptional depth of expertise.
News Article | May 24, 2017
Brussels event on 4th October 2017 unites experts in digital security/cybercrime, ICT and the transport industry to highlight threats and discuss solutions Brussels, 24 May 2017 – A key conference in digital security for the rail industry has been announced for later this year. Set to take place on 4th October 2017 in Brussels, the CyberSecurity4Rail event will bring together experts in cybercrime and digital security, plus leaders in ICT and representatives from transport and railway companies to discuss the threats and set out a vision for safer, more secure digital communications and data networks in the transport industry. The recent ransomware attacks on public services and organisations across the globe have illustrated all too clearly the vulnerabilities of our connected world. The rail and other transport industries were not immune from the attack and this serves to reinforce the message that we must all work together to put robust solutions in place to protect our data and networks from further incursion and interference. CyberSecurity4Rail will draw on the experience of recent incidents and the expertise of those who are working to protect systems and prevent cyberthreat. The conference, to be held at Hotel Thon EU in the European Quarter in Brussels, is entitled CyberSecurity4Rail: Helping European Railways to Build Digital Security through Cooperation and will address senior representatives from across the industries, including top EU officials, members of rail organisations and other transport-related bodies. Speakers will include representatives from the European Union Agency for Railways (EUAR), the Community of European Railway and Infrastructure Companies (CER), the International Union of Railways, (UIC), as well as European Union bodies such as DG-MOVE, DG-CONNECT and the European Network and Information Security Agency ENISA, along with European Police and Crime perspectives. It will also bring together representatives from other modes of transport, especially air, as they begin to face similar threats and challenges. Confirmed speakers to date include Dr Josef Doppelbauer, Executive Director of EUAR; Dr Florent Frederix, DG CONNECT H1, European Commission; Dr Libor Lochman, Executive Director of CER; Corrado Giustozzi, Senior Cyber Security Strategist at SELTA and ENISA, Philippe-Emmanuel Maulion, Chief Information Security Officer of SITA, the air transport ICT company, Guus van Es, General Manager for BT’s Global Security Consulting and Marie-Hélène Bonneau of UIC, presenting on Cyrail, a European rail industry cyber security project. Hit Rail’s General Manager, Antonio Lopez, and Technical Director, Mick Haynes, will also be speaking at the event. Today, connectivity has become key to many critical business applications and functions in the railway industry. It is supported by a diversity of complex technologies and interconnected communication networks and, like many other parts of the transportation industry, fully depends on these digital technologies. At the same time, digitalization has created new security risks that can be exploited for malicious intent. Digital crime is becoming more sophisticated and better organised. Hackers are constantly finding ways to break digital security and such cyber attacks can cause enormous reputational damage and loss of revenue. As this threat grows, digital security alongside physical safety is becoming a key issue on the agendas of all major transport organisations. Hosted by global connectivity experts Hit Rail B.V., the CyberSecurity4Rail Conference will focus on the key question: “Are European railways ready to prevent digital crime?” It will take stock of the current situation and identify present and future threats, also looking to predict developments, face challenges and suggest practical solutions, primarily through opportunities for cooperation between railway and other transport organisations and international initiatives. It will also present several use cases from the industry of how transport organisations are beginning to fight back against the threat of cybercrime. Antonio Lopez, General Manager of Hit Rail, said: “Security, especially in the transport industry, is constantly in the news today – and cyber security is becoming a growing part of the threat we face. Many companies across the transport industry are struggling to stay on top of the digital security challenges in today’s world. Railways as businesses must act to protect their systems and data. We believe that digital security is not a question of competition, but cooperation. Working with policy makers, regulators, peers within the railway industry, companies in other transport sectors and experts in digital security, the railways can make it much harder for would-be perpetrators of digital crime to succeed.” CyberSecurity4Rail is the third in a series of workshops that Hit Rail has held for the railway industry. For more information on the conference and how to take part please go to our website at: https://www.hitrail.com/events/cyber-security-for-railways-conference-2017 About Hit Rail B.V. Hit Rail B.V. is a private Dutch company created in 1990 and owned by 12 European railway companies. Its purpose is to help European railway companies to carry out international projects in related fields of data communications and information technology. Hit Rail is responsible for managing international private data communications infrastructure and message brokering services on behalf of its shareholders and customers. Its services are used by some 50 railway companies from 21 countries. All Hit Rail customers’ data centres and company networks are interconnected by a pan-European IP-based VPN (Virtual Private Network) named Hermes VPN, which is supplied by British Telecom (BT) and managed by Hit Rail. In 2013, the company launched its HEROS platform as a family of solutions that delivers benefits to the railway companies across Europe, by enabling message interoperability across disparate platforms between railway applications in passenger, freight and infrastructure for IT communications. For more information please visit http://www.hitrail.com or send an email to firstname.lastname@example.org.
News Article | April 28, 2017
PARIS, April 28, 2017 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q1 2017 Change Change at CER Change at CER and CS(1) Business net income(2) €1,795m +4.2%...
News Article | May 5, 2017
Sales are up by 21.2% of which 6.8% organic growth Automotive market: growth is 8.6% on a market that has increased by 5.8% The published net sales are up by 8.6% at the end of March 2017 (the evolution is + 6.8% at constant perimeter & CER) at a period when the global automotive production has increased by 5.8%. Net sales in the "on-board networks protection" business - which account for 63% of overall sales - are up by 9.9% (+ 8.1% at constant perimeter & CER). The "technical tubing for fluid transfer" business is up by + 20.6% (+ 18.0% at constant perimeter & CER). The "mechanical parts assembly" business is down by - 21.4%. The impact of the exchange rates on sales is favorable of 0.7 M€ at the end of March. At constant perimeter and exchange rate, sales are up as follows: Sales in the automotive division - excluding the "mechanical parts assembly" business - are up by 9.3% of which 7% in Europe-Africa. Sales in the specialty markets are up by 113%. This very sharp rise is due to: The revenue increase in the first quarter confirms DELFINGEN's growth potential, in line with its strategic plan: leadership in on-board networks protection and diversification in fluid transfer technical tubing. With the increase of media content and safety constraints, the development of hybrid and electric engines along with the advent of connected and autonomous cars, wire harnesses have truly become the nervous system of a vehicle. DELFINGEN's mission is to protect it by providing ever more higher-value innovative solutions. On the basis of a 2017 global automotive production forecast of +1 to +2%, DELFINGEN's growth objectives are in the range of 5% with an improvement of its operating income. DELFINGEN, a global automotive supplier and a leading manufacturer of on-board networks protection solutions and fluid transfer tubing. NYSE Alternext Paris - ISIN code: FR 0000054132 - Mnemonic: ALDEL Next press release: 28/07/2017 - 2017, 1st- half-year net sales Contact: M. Christophe CLERC: +33 (0)188.8.131.52.00 - www.delfingen.com
News Article | May 2, 2017
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 2, 2017) - China Education Resources, Inc. ("CER") (TSX VENTURE:CHN)(OTCQX:CHNUF), an edu-tech company with leading technology in intelligent system and content provider for online learning, training courses and social media for teachers, students and education professionals, announced its audited financial results for the year ended December 31, 2016. All figures are expressed in U.S. dollars except otherwise stated. For the year ended December 31, 2016, CER reported aggregate sales revenue of $13,420,347 as compared to $12,715,834 for the same period in 2015. The Company recognized a net profit of $916,204 attributable to the shareholders for the year ended December 31, 2016 as compared to a net loss of $395,519 attributable to the shareholders for the same period in 2015. The 2016 financial highlights are as summarized as follows: Our sales revenue was generated in China and in Chinese local currency, Renminbi ("RMB"). If we calculate the percentage change using our functional currency RMB, we actually had an 11.53% increase in total revenue in 2016 as compared with the same period in 2015, which was much higher than the corresponding 5.54% in US dollars ("USD") mentioned above as different exchange rates were used for the conversion of RMB into USD for different period of time. The sales revenue and net income attributable to shareholders for the twelve-month period ended December 31, 2016 both increased as compared with the same period of last year. CER is very delighted on having a strong operational framework and achieved both accelerated top-line growth and continued solid bottom-line performance in 2016, reflecting continuous improvement in product mix, brand recognition and optimizing the business operations. "We are very pleased with our overall performance for the year ended December 31, 2016 and also very happy to reverse $1.33 million income tax payables on the consolidated balance sheet, which were overstated for more than 10 years," said Chengfeng Zhou, CEO, China Education Resources. "The operating performance of the company is expected strong for the year 2017. We have been approached by different institutions and companies from various countries since we launched our soccer education online platform which integrates with the functions of CER online teacher training platform and school platform. We expect our unique and comprehensive blend of education resources and services will provide CER with long-term revenue potential. We are encouraged by the increase in utilization of our internet platform and educational social network, which work together with our existing online/offline products. We will update our shareholders on the progress." For more information, please visit www.chinaeducationresources.com or Email: email@example.com. In collaboration with China's education administrators and experts, China Education Resources has been helping to transform the curriculum of the world's largest educational system. Recognizing the need to address education reform changes, China Education Resources has created educational tools and curriculum for China's entire kindergarten through twelfth grade system. The Company is playing an integral part in transforming China's educational system through helping to convert the existing educational system from a memory-based learning system to a creative thinking and interactive approach. Presently, China Education Resources has over 1 million kindergarten through twelfth grade teachers registered through its Web portal. Certain statements made herein, and other statements relating to matters that are not historical facts and statements of our beliefs, intentions and expectations about developments, results and events which will or may occur in the future, constitute "forward-looking information" within the meaning of applicable securities legislation. Forward-looking information and statements are typically identified by words such as "anticipate", "could", "should", "expect", "seek", "may", "intend", "likely", "plan", "estimate", "will", "believe" and similar expressions suggesting future outcomes or statements regarding an outlook. All such forward-looking information and statements are based on certain assumptions and analysis made by China Education Resources, Inc.'s management in light of their experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. These statements, however, are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information or statements. Important factors that could cause actual results to differ from these forward-looking statements include those described under the heading "Risks and Uncertainties" elsewhere in the Company's MD&A filed at www.SEDAR.com. The reader is cautioned not to place undue reliance on forward-looking information or statements. Except as required by law the Company does not assume the obligation to revise or update these forward looking statements after the date of this document or to revise them to reflect the occurrence of future, unanticipated events. The TSX Venture Exchange has not reviewed, and does not accept, responsibility for the adequacy or accuracy of the contents of this press release.
News Article | March 1, 2017
Cerenis Therapeutics (Paris:CEREN) (Euronext: CEREN ― ISIN: FR0012616852), an international biopharmaceutical company dedicated to the discovery and development of innovative therapies for treating cardiovascular and metabolic diseases, announces results from the global CARAT Phase II study with CER-001 in post-acute coronary syndrome (ACS) patients. The findings show no statistical difference between CER-001 and placebo in the study’s primary endpoint of percentage change from baseline in percent atheroma volume (PAV) as measured by intravascular ultrasound (IVUS) compared with placebo. The full results will be presented on March 18, 2017 at the Annual American College of Cardiology Scientific Sessions in Washington DC. CARAT is a double-blind, placebo-controlled study designed to assess the impact of CER-001 on the regression of atherosclerotic plaque in post-ACS patients by measuring PAV using IVUS imaging of the coronary vascular wall. A total of 301 randomized patients were administered 3 mg/kg of CER-001 or placebo in a 1:1 ratio on Day 1 and weekly thereafter for a total of 10 infusions, followed by a two-week observation period. The study was conducted at sites in Australia, Hungary, the Netherlands and the United States. Dr. Jean-Louis Dasseux, founder and CEO of Cerenis, said, “We are surprised and disappointed by the topline findings in the CARAT trial, which are inconsistent with the results of previous studies with CER-001 in this patient population. We will continue to analyze the CARAT data in order to understand these results while also pursuing our other clinical programs. The TANGO Phase III clinical study in patients with a genetic HDL deficiency is ongoing.” Dr. Dasseux added, “In the near term, we plan to accelerate the development of our other pipeline drugs whose mode of action is different from CER-001. In addition, we will launch a Phase I clinical study for CER-209 in NASH/NAFLD, two major worldwide health issues, where preclinical results underlie the strong therapeutic potential of this small molecule drug.” Conference call today, on 1st March, 2017 at 6:00 PM (CET) Jean-Louis Dasseux, founder and CEO of Cerenis Therapeutics will hold a conference call in English on 1st March, 2017 at 6:00 AM (CET). To access this conference call, please dial the applicable number: From France: 01 70 77 09 41 From UK: +44 - 2033679456 From the United State: +1 6467224908 About CER-001 CER-001 is an engineered complex of recombinant human apolipoprotein A-1 (apoA-I), the major structural protein of HDL, and phospholipids, designed to mimic the structure and function of natural, HDL. It is intended to increase apoA-I and the number of HDL particles transiently, to stimulate the removal of excess cholesterol and other lipids from tissues including the arterial wall and to transport them to the liver for elimination through a process called Reverse Lipid Transport. About Cerenis Therapeutics: www.cerenis.com Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative therapies for the treatment of cardiovascular and metabolic diseases. Cerenis is developing a portfolio of therapies, including HDL mimetics for patients with HDL deficiency. Since its inception in 2005, the company has been funded by top-tier investors including Sofinnova Partners, HealthCap, Alta Partners, EDF Ventures, Daiwa Corporate Investment, TVM Capital, Orbimed, IRDI/IXO Private Equity and Bpifrance. In March 2015 Cerenis completed an IPO on Euronext raising €53.4m.
News Article | March 1, 2017
Jack Price, founder of Price Rubin & Partners and concert pianist formerly known as Dickran Atamian, announces the U.S. tour of the distinguished National Symphony Orchestra of Ukraine. The Price Rubin artists will kick off their tour on Thursday, March 9, at 7:30 p.m. at the Armstrong Auditorium on the campus of Herbert W. Armstrong College, 14400 S. Bryant Road, Edmond, OK, as part of the Armstrong International Cultural Foundation Performing Arts Series. “This is a golden opportunity to hear the leading symphonic organization of Ukraine, which is the most recorded orchestra located in any former Soviet territory,” said Price. “The National Symphony Orchestra of Ukraine will be performing the works of Dvorak and Prokofiev. They will appear with Kiev-born pianist Alexei Grynyuk, who won first prizes at the Vladimir Horowitz International Piano Competition in Kiev and the Shanghai International Piano Competition in China.” Formed in 1918, the National Symphony Orchestra of Ukraine has a storied history. It has collaborated with most of the major conductors, composers and soloists of the 20th century, including music directors Natan Rakhlin, Fedor Glushchenko, Theodore Kucharand Volodymyr Sirenko; legendary guest conductors Stokowski, Markevitch, Sanderling, Mravinsky, Kondrashin and Rozhdestvensky; and famed soloists Rubinstein, Menuhin, Stern, Oistrakh, Richter, Rostropovich, Gilels, Kogan, Kremer and Carreras. The National Symphony Orchestra of Ukraine was also entrusted with the premier performances of the works by Shostakovich, Khachaturian and Lyatoshynsky. Since 1993, it has toured worldwide and has released more than 100 sound recordings on Naxos, Marco Polo and Brilliant Classics, receiving the highest international acclaim, including two Grammy nominations. To purchase tickets for the National Symphony Orchestra of Ukraine performance at the Armstrong Auditorium on March 9, please visit http://www.armstrongauditorium.org/performance/national-symphony-orchestra-of-ukraine. About Jack Price, Price Rubin & Partners Artist Management Jack Price helps artists develop their individual market branding and career milestones. The Price Rubin & Partners staff makes thousands of calls every month to decision-makers who are in charge of talent acquisition for concerts, corporate events and fundraisers. They offer real-time reporting where artists can see their campaign (which is personally supervised by Jack) unfolding second by second. Price Rubin stands for transparency and accountability in artist management today. For more information, please call (310) 254-7149, (PRI) CER-UBIN or visit http://www.pricerubin.info. About the NALA™ The NALA offers small and medium-sized businesses effective ways to reach customers through new media. As a single-agency source, the NALA helps businesses flourish in their local community. The NALA’s mission is to promote a business’ relevant and newsworthy events and achievements, both online and through traditional media. For media inquiries, please call 805.650.6121, ext. 361.
News Article | February 17, 2017
Cerenis Therapeutics (Paris:CEREN) (FR0012616852- CEREN - Eligible PEA-PME), société biopharmaceutique internationale spécialisée dans la découverte et le développement de thérapies HDL («bon cholestérol») innovantes pour traiter les maladies cardiovasculaires et métaboliques, annonce ce jour ses résultats annuels 2016, arrêtés par le conseil d’administration du 17 février 2017. Les procédures d’audit sur les comptes sociaux et consolidés ont été effectuées par les commissaires aux comptes et le rapport de certification est en cours d’émission. Cyrille Tupin, Directeur Financier de Cerenis, déclare : « Le niveau de consommation de trésorerie, conforme à nos attentes, est directement lié aux avancées cliniques de nos deux principaux produits, CER-001 et CER-209, potentielles percées thérapeutiques innovantes adressant des indications qui comptent parmi les enjeux majeurs de santé publique au plan mondial que sont les maladies cardiovasculaires et les stéatoses hépatiques. Les solides ressources financières dont dispose actuellement la Société nous autorisent à envisager sereinement les développements cliniques prévus en 2017, relatifs à la phase I de CER-209 et TANGO, la phase III de CER-001 ». Conformément aux attentes, Cerenis Therapeutics n'a pas généré de chiffre d'affaires au cours de l’exercice 2016, les produits de la Société étant en phase de recherche et développement. Actuellement, Cerenis Therapeutics poursuit le développement clinique de CER-001, mimétique de la particule pré-bêta HDL contenant de l'apoA-I humaine recombinante, suite à l’achèvement de l’étude CARAT, une étude clinique de phase II, chez des patients post Syndrome Coronarien Aigu (post-SCA), et au travers de TANGO, une étude de phase III actuellement en cours chez des patients atteints d’Hypoalphalipoprotéinémie Familiale Primaire (FPHA : déficience en HDL due à des défauts génétiques et regroupant différentes maladies orphelines). Les résultats de CARAT et TANGO sont respectivement attendus au premier et troisième trimestre 2017. Cerenis continue aussi le développement clinique de CER-209, un nouvel agoniste spécifique du récepteur P2Y13 pour le traitement des Hépatites Graisseuses Non Alcooliques (NAFLD) et de la StéatoHépatite Non Alcoolique (NASH). Le recrutement des premiers sujets devrait débuter au premier trimestre 2017. Les dépenses de R&D s’élèvent à 17,0 M€ en 2016 contre 12,6 M€ en 2015. Leur augmentation traduit principalement la poursuite des études cliniques CARAT et TANGO. Les dépenses concernent, en majeure partie, les frais de personnel induits par les travaux de recherche et développement ainsi que les frais de sous-traitance et de consultants liés aux études et à la gestion des brevets. Dans une moindre mesure, l’augmentation des paiements en actions, conformément à l’application de la norme comptable IFRS 2 « Paiement fondé sur des actions », participe également à l’augmentation des dépenses de R&D. Le recrutement des patients s’est achevé en août 2016, et le dernier patient a reçu la dixième et ultime administration de CER-001 ou de placebo au quatrième trimestre 2016. Les résultats de l’étude CARAT sont attendus au plus tard à la fin du premier trimestre 2017. Le risque de récidive de crise cardiaque chez les patients qui viennent de subir un syndrome coronarien aigu (SCA) reste très élevé et représente un besoin médical important non satisfait. CER-001 apporterait une chance unique de réduire le risque de récidive dans les premiers mois suivant la survenance d’un SCA en réduisant rapidement les plaques d’athérome. CER-001, en complément des traitements conventionnels post-SCA incluant les traitements hypolipidémiants de longue durée, pourrait permettre une réduction additionnelle du taux de morbidité et de mortalité et pourrait devenir par conséquent le traitement standard pour les patients ayant subi un SCA. La publication des résultats de l’étude LOCATION dans le journal scientifique de référence de l’European Atherosclerosis Society (EAS), en juin 2016, témoigne de l’intérêt de la communauté scientifique pour CER-001 et par conséquent de la solidité de la preuve de concept. L’étude LOCATION, dont les résultats avaient été annoncés en juillet 2015, a fourni la première preuve du ciblage sélectif par CER-001 des plaques d'athérosclérose chez les patients, et a souligné le rôle de la perméabilité de ces plaques pour la pénétration d’un mimétique de HDL dans celles-ci. L'étude a évalué huit patients présentant une sténose carotidienne supérieure à 50%. Ces patients ont reçu une administration de CER-001 (3 mg/kg) marquée au Zirconium-89, un traceur adapté à l'imagerie TEP/CT, pour déterminer dans quelle proportion CER-001 cible et pénètre les plaques d'athérosclérose. L’effet sur la capacité d’efflux de cholestérol, un marqueur inversement proportionnel à l'incidence des événements cardiovasculaires1, a aussi été déterminé. En décembre 2016, la US Food and Drug Administration (FDA) a informé Cerenis Therapeutics que CER-209 pouvait entrer en développement clinique. Cette autorisation de la FDA (IND, Investigational New Drug application) porte sur une étude clinique de phase I pour le candidat-médicament CER-209, un agoniste du récepteur P2Y13, chez des volontaires sains, dans les NAFLD et la NASH. CER-209, un agoniste innovant et sélectif du récepteur P2Y13, entraîne une diminution des plaques d’athérome situées au niveau de l’aorte et des carotides ainsi qu’une régression importante de l’accumulation des graisses hépatiques (stéatose) dans un modèle préclinique validé. Cerenis prévoit de débuter le recrutement des sujets au premier trimestre 2017. Les résultats précliniques de CER-209 ont été présentés en février 2016 lors du Symposium International Asian Pacific Association for the study of the liver (APASL) qui s’est déroulé à Tokyo. Deux posters ont été présentés à cette occasion. A propos de Cerenis : www.cerenis.com Cerenis Therapeutics Holding est une société biopharmaceutique internationale dédiée à la découverte et au développement de thérapies HDL innovantes pour le traitement des maladies cardiovasculaires et métaboliques. Le HDL est le médiateur primaire du transport retour du cholestérol (ou RLT), la seule voie métabolique par laquelle le cholestérol en excès est retiré des artères et transporté vers le foie pour élimination du corps. Cerenis développe un portefeuille de thérapies HDL, dont des mimétiques de particules HDL pour induire la régression rapide de la plaque d’athérome chez des patients à risque tels ceux atteints de syndrome coronarien aigu et les patients souffrant de déficience en HDL, ainsi que des molécules qui augmentent le nombre de particules HDL afin de traiter les patients atteints d’athérosclérose et de maladies métaboliques associées telles que la StéatoHépatite Non Alcoolique (NASH) et les Hépatites Graisseuses Non Alcooliques (NAFLD). A propos du CER-001 CER-001 est un complexe obtenu par bioingénierie contenant de l'apoA-I humaine recombinante, la protéine naturelle des HDL, et des phospholipides dont un chargé négativement. Sa composition a été optimisée afin d'imiter la structure et les propriétés bénéfiques des HDL naturelles naissantes, autrement connues sous la dénomination pré-bêta HDL. Son mécanisme d'action est d'augmenter l'apoA-I et le nombre de particules HDL de façon transitoire. Ceci afin de stimuler l’élimination du cholestérol et autres lipides en excès des tissus dont la paroi artérielle puis de les transporter vers le foie pour élimination via la voie métabolique appelée Transport Retour des Lipides ("Reverse Lipid Transport" ou RLT). Les précédentes études cliniques de phase II ont apporté d’importants résultats démontrant l’efficacité de CER-001 à faire régresser l’athérosclérose dans plusieurs lits vasculaires distincts chez des patients représentant l’ensemble du spectre de l’homéostasie du cholestérol. La totalité des résultats à ce jour indiquent que CER-001 effectue toutes les fonctions des pré-bêta HDL naturelles et a le potentiel de devenir sur le marché le meilleur de la classe des mimétiques de HDL. A propos du CER-209 CER-209 est le premier candidat-médicament dans sa catégorie, celle des agonistes du récepteur P2Y13. Le récepteur P2Y13 est un membre de la famille bien connue des récepteurs P2Y, qui comprend notamment le récepteur P2Y12, cible de médicaments à succès tels que l’agent anti-thrombotique Clopidogrel (Plavix®). CER-209 est un agoniste spécifique du récepteur P2Y13 et il n’interagit pas avec le récepteur P2Y12. Les études précliniques ont montré que le CER-209 agit sur la dernière étape de la voie métabolique de transport retour des lipides, ou RLT, augmente la reconnaissance des HDL par le foie et facilite l’élimination des lipides dans les selles, conduisant finalement à la régression de la plaque d’athérome. En raison des effets métaboliques favorables observés sur le foie au cours des expériences précliniques, le CER-209 pourrait offrir un mécanisme nouveau pour le traitement de la StéatoHépatite Non Alcoolique (NASH) et des Hépatites Graisseuses Non Alcooliques (NAFLD).
News Article | February 27, 2017
Ian Page, Chief Executive Officer: "Our core portfolio continues to grow, the enhanced product pipeline is delivering new products and good progress has been made on the rationalisation and integration of our recent acquisitions." The Group has performed strongly throughout the first six months of the financial year ending 30 June 2017 (the Period). This result has been driven by a solid revenue performance in our core businesses, good market penetration from recently launched pipeline products and a strong performance from our recent acquisitions. The operating profit performance has been enhanced by the successful rationalisation and integration of these acquisitions, prudent cost control in our core businesses and a significant favourable foreign exchange tail wind. - Total Group revenue of £172.6 million, a growth of 34.7% at Constant Exchange Rate (CER) (55.9% at Actual Exchange Rate (AER)). - Core (excluding acquisitions) European Pharmaceuticals (EU Pharmaceuticals) Segment revenue growth of 5.9% at CER (20.0% at AER). - Core North American Pharmaceuticals (NA Pharmaceuticals) Segment revenue growth of 10.2% at CER (31.7% at AER). - Sales growth across all product groups; Companion Animal Products (CAP), Food producing Animal Products (FAP), Equine and Diets. - Underlying operating profit increased by 28.6% at CER (47.1% at AER). - Net cash inflow from underlying operating activities of £43.9 million with a cash conversion of 124.0%. The Group continues to perform well with current trading meeting management expectations. Our core portfolio continues to grow, the enhanced product pipeline is delivering new products and good progress has been made on the rationalisation and integration of our recent acquisitions. The Board therefore remains confident in our strategy, our future prospects and our expectations for full year performance. To read the 2017 Half Yearly Report in full please visit http://www.dechra.com All growth rates for both underlying and reported financial results included in the Dechra report are at CER, unless otherwise stated. This shows the year on year growth rates as if exchange rates had remained the same as in the previous year. The Group presents a number of non-GAAP Alternative Performance Measures (APM's). This allows investors to understand better the underlying performance of the Group, by excluding amortisation of acquired intangibles and impairment (if any) of acquired intangibles, acquisition expenses, fair value of uplift of inventory acquired through business combinations, rationalisation costs, loss on extinguishment of debt, and fair value and other movements on deferred and contingent consideration. EBITDA is defined as underlying earnings before interest, tax, depreciation and amortisation.
News Article | February 15, 2017
CALGARY, ALBERTA--(Marketwired - Feb. 9, 2017) - Canadian Equipment Rentals Corp. ("CER" or the "Company") (TSX VENTURE:CFL) is pleased to announce that further to its press release dated January 31, 2017, it has completed the sale of the assets of its wholly-owned subsidiary, 4-Way Equipment Rentals Corp. to Cooper Rentals Canada Inc. Gross cash proceeds from the transaction will be approximately $8.5 million. Net proceeds after transaction costs and post-closing adjustments will be applied against CER's senior indebtedness. About Canadian Equipment Rentals Corp. Canadian Equipment Rentals Corp. is a Canadian public corporation and parent company to Zedcor Energy Services Inc. ("Zedcor"). Zedcor is engaged in the rental of surface equipment and accommodations to the Western Canadian Oil and Gas Industry. The Company trades on the TSX Venture Exchange under the symbol "CFL". About Cooper Rentals Canada Inc. Cooper Rentals Canada Inc., headquartered in Mississauga, Ontario, is a full-service construction equipment rental company, servicing contractors across Ontario and Quebec. Cooper specializes in the rental of compact, aerial and heavy construction equipment while providing a wide range of related services and supplies. Forward-Looking Statements and Information Certain statements included or incorporated by reference in this press release constitute forward-looking statements or forward-looking information. Forward-looking statements or information may contain statements with the words "anticipate", "believe", "expect", "plan", "intend", "estimate", "propose", "budget", "should", "project", "would have realized', "may have been" or similar words suggesting future outcomes or expectations. Forward-looking statements in this press release include the payment of net proceeds after transaction costs against the CER senior indebtedness. Although the Company believes that the expectations implied in such forward-looking statements or information are reasonable, undue reliance should not be placed on these forward-looking statements because the Company can give no assurance that such statements will prove to be correct. Forward-looking statements or information are based on current expectations, estimates and projections that involve a number of assumptions about the future and uncertainties. Although management believes these assumptions are reasonable, there can be no assurance that they will be proved to be correct, and actual results will differ materially from those anticipated. For this purpose, any statements herein that are not statements of historical fact may be deemed to be forward-looking statements. The forward-looking statements or information contained in this press release are made as of the date hereof and the Company assumes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new contrary information, future events or any other reason, unless it is required by any applicable securities laws. The forward-looking statements or information contained in this press release are expressly qualified by this cautionary statement. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.